Pan‐HDAC inhibitors have been approved for the treatment of hematologic malignancies, and HDAC6‐selective inhibitors are actively being developed and undergoing clinical trials.[46, 47] However, the development of USP9X‐selective inhibitors has been relatively underexplored, with existing compounds exhibiting limited selectivity. This evidence concerns the gene HDAC9 and hematologic disorder.